ライフサイエンスコーパス: urokinase-type plasminogen activator

1 n through the expression of the receptor for urokinase type plasminogen activator.

2 ly enhances the activation of plasminogen by urokinase type plasminogen activator.

3 iation, and this cleavage may be mediated by urokinase-type plasminogen activator.

4 aprotinin, and the aminoterminal fragment of urokinase-type plasminogen activator.

5 oteins intercellular adhesion molecule-1 and urokinase-type plasminogen activator.

6 of endothelial cell integrin alphavbeta3 and urokinase-type plasminogen activator.

7 but not thrombin, coagulation factor Xa, or urokinase-type plasminogen activator.

8 quent cell movement and migration by binding urokinase-type plasminogen activator.

9 a more effective inactivator of tPA than of urokinase-type plasminogen activator.

10 nt hK2, which readily activated single chain urokinase-type plasminogen activator.

11 th factor 1, leukemia inhibitory factor, and urokinase-type plasminogen activator.

12 U1) by costimulation with phorbol esters and urokinase-type plasminogen activator.

13 activities of matrix metalloproteinase-2 and urokinase-type plasminogen activator.

14 is the main inhibitor of the tissue type and urokinase type plasminogen activators.

15 the reactions of PAI-1 with tissue-type and urokinase-type plasminogen activators.

16 comitant increased expression of its target, urokinase-type plasminogen activator, a known tumor-asso

17 for fibrinolysis, increased tissue-type and urokinase-type plasminogen activators, a relatively decr

18 ts displayed moderately reduced single-chain urokinase-type plasminogen activator activation.

19 t the effect of L-MIM involves a decrease in urokinase-type plasminogen activator activity.

20 greatly reduced the activity of both tPA and urokinase-type plasminogen activator after HI.

21 , leading to the up-regulation of macrophage urokinase type plasminogen activator and matrix metallop

22 and stimulated the expression of macrophage urokinase type plasminogen activator and MMP-9.

23 ibrinolytic cascade by colocalizing with the urokinase type plasminogen activator and receptor comple

24 Pdef also results in the down-regulation of urokinase-type plasminogen activator and activation of t

25 d secretion of matrix metalloproteinases and urokinase-type plasminogen activator and an increase in

26 at the translational level by eIF3e included urokinase-type plasminogen activator and apoptotic regul

27 ement with these findings, reduced levels of urokinase-type plasminogen activator and elevated levels

28 turn induced expression of VEGF, MMP-9, and urokinase-type plasminogen activator and increased migra

29 The urokinase-type plasminogen activator and its receptor (u

30 ation of collagen IV, and their secretion of urokinase-type plasminogen activator and its receptor.

31 associated with expression of high levels of urokinase-type plasminogen activator and low levels of T

32 The urokinase-type plasminogen activator and membrane-type M

33 dative phenotype of macrophages via enhanced urokinase-type plasminogen activator and MMP-9 expressio

34 cultures stimulates their expression of both urokinase-type plasminogen activator and MMP-9, and the

35 serpin inhibits tPA and, to a lesser extent, urokinase-type plasminogen activator and plasmin.

36 the expression of matrix metalloproteinases, urokinase-type plasminogen activator, and cytokines in h

37 While matrix metalloproteinases, urokinase-type plasminogen activator, and cytokines play

38 m via mechanisms involving both cell surface urokinase-type plasminogen activator, and interactions b

39 variant failed to activate the single-chain urokinase-type plasminogen activator, and the G221A and

40 sminogen, tissue-type plasminogen activator, urokinase-type plasminogen activator, and urokinase-type

41 the inhibition of interleukin (IL)-6, IL-8, urokinase-type plasminogen activator, and VEGF productio

42 activated receptor 2 (PAR2) and single-chain urokinase-type plasminogen activator are proteins that a

43 roduced plasminogen activators (i.e. tPA and urokinase-type plasminogen activator) are responsible fo

44 ng rate constant (klim) of RCL insertion for urokinase-type plasminogen activator at pH 6.2-8.0 and f

45 complex with the amino-terminal fragment of urokinase-type plasminogen activator (ATF), at the resol

46 n (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, caveolin-1 and Slu

47 MMP-12 induction in plasminogen(Plg)-treated urokinase-type plasminogen activator-deficient macrophag

48 (6) integrin, called alpha(6)p, generated by urokinase-type plasminogen activator-dependent cleavage

49 promatrilysin to an active elastolysin via a urokinase-type plasminogen activator-dependent pathway.

50 Five proteases were identified: urokinase-type plasminogen activator, factor XII, protei

51 mice carrying a mouse major urinary protein-urokinase-type plasminogen activator fusion transgene.

52 mmune-deficient transgenic mice carrying the urokinase-type plasminogen activator gene driven by the

53 upon activation of PepO-bound plasminogen by urokinase-type plasminogen activator, generated plasmin

54 ombinant PSA failed to activate single chain urokinase-type plasminogen activator, in contrast to the

55 he expression of its downstream target gene, urokinase-type plasminogen activator, in metastatic panc

56 al (Beas2B) cells decreased basal as well as urokinase-type plasminogen activator-induced PAI-1 expre

57 Plasmin, generated by the endogenous urokinase-type plasminogen activator, is not an efficien

58 (ERK)1/2 activation, and decreases levels of urokinase-type plasminogen activator, known downstream e

59 immunodeficient BALB-DeltaRAG/gamma(c) -uPA (urokinase-type plasminogen activator) mice, freshly thaw

60 gonucleotides reduced the levels of ETS1 and urokinase-type plasminogen activator mRNAs.

61 icellular proteolytic cascades by activating urokinase-type plasminogen activator on the cell surface

62 in absence of ADAMTS13, after activation by urokinase-type plasminogen activator or the thrombolytic

63 in(i) acts specifically; it does not inhibit urokinase-type plasminogen activator, plasmin, chymotryp

64 owing: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activat

65 cluding very low density lipoprotein (VLDL), urokinase-type plasminogen activator:plasminogen activat

66 gen activator precursor (PLAT; 2.8-fold) and urokinase-type plasminogen activator precursor (PLAU; 2.

67 The binding of the zymogenic form of urokinase-type plasminogen activator (pro-uPA) to its sp

68 e epsilon readily converted single-chain pro-urokinase-type plasminogen activator (pro-uPA/scuPA) int

69 an effect on the expression/function of the urokinase-type plasminogen activator protease uPA/uPAR s

70 or has been developed for rapid detection of urokinase type plasminogen activator receptor (uPAR) - a

71 The expression of urokinase type plasminogen activator receptor (uPAR) and

72 Circulating levels of soluble forms of urokinase-type plasminogen activator receptor (suPAR) ar

73 Recent studies describe soluble urokinase-type plasminogen activator receptor (suPAR) as

74 Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) ha

75 Serum soluble urokinase-type plasminogen activator receptor (suPAR) is

76 ous studies have demonstrated that a soluble urokinase-type plasminogen activator receptor (suPAR) pl

77 Increased plasma level of soluble urokinase-type plasminogen activator receptor (suPAR) wa

78 ulin (beta-2 m), neopterin and suPAR soluble urokinase-type plasminogen activator receptor (suPAR) wa

79 In addition, Pdcd4 knockdown stimulates urokinase-type plasminogen activator receptor (u-PAR) an

80 The transcriptionally regulated urokinase-type plasminogen activator receptor (u-PAR) co

81 The urokinase-type plasminogen activator receptor (u-PAR) co

82 The urokinase-type plasminogen activator receptor (u-PAR) ha

83 The urokinase-type plasminogen activator receptor (u-PAR) pl

84 Mice lacking the urokinase-type plasminogen activator receptor (u-PAR), a

85 elial growth factor results in clustering of urokinase-type plasminogen activator receptor (uPAR) and

86 s accompanied by increased expression of the urokinase-type plasminogen activator receptor (uPAR) and

87 adenovirus-mediated expression of antisense urokinase-type plasminogen activator receptor (uPAR) and

88 Because beta-catenin and its target genes urokinase-type plasminogen activator receptor (uPAR) and

89 ocytosis of multiple ligands, transports the urokinase-type plasminogen activator receptor (uPAR) and

90 In this study, we identified the urokinase-type plasminogen activator receptor (uPAR) as

91 Urokinase-type plasminogen activator receptor (uPAR) bin

92 Previous studies have indicated that the urokinase-type plasminogen activator receptor (uPAR) can

93 Signaling by urokinase-type plasminogen activator receptor (uPAR) can

94 a serine proteinase that upon binding to the urokinase-type plasminogen activator receptor (uPAR) cat

95 The urokinase-type plasminogen activator receptor (uPAR) dri

96 at in adult mice with a null mutation in the urokinase-type plasminogen activator receptor (uPAR) gen

97 The urokinase-type plasminogen activator receptor (uPAR) has

98 in the mid-1980s, the cell membrane-anchored urokinase-type plasminogen activator receptor (uPAR) has

99 The role of urokinase-type plasminogen activator receptor (uPAR) in

100 explore the potential of PET imaging of the urokinase-type plasminogen activator receptor (uPAR) in

101 The urokinase-type plasminogen activator receptor (uPAR) is

102 Moreover, ErbB2-mediated upregulation of urokinase-type plasminogen activator receptor (uPAR) is

103 The urokinase-type plasminogen activator receptor (uPAR) is

104 The urokinase-type plasminogen activator receptor (uPAR) is

105 The urokinase receptor urokinase-type plasminogen activator receptor (uPAR) is

106 ar accumulation of beta-catenin, and induces urokinase-type plasminogen activator receptor (uPAR) mRN

107 cells, interaction between vitronectin with urokinase-type plasminogen activator receptor (uPAR) on

108 The urokinase-type plasminogen activator receptor (uPAR) pro

109 Expression levels of the urokinase-type plasminogen activator receptor (uPAR) rep

110 e glycosylphosphatidyl-inositol (GPI)-linked urokinase-type plasminogen activator receptor (uPAR) rev

111 We report a new member of the Ly-6/urokinase-type plasminogen activator receptor (uPAR) sup

112 The expression of urokinase-type plasminogen activator receptor (uPAR) was

113 We identify the urokinase-type plasminogen activator receptor (uPAR)(11)

114 ule (ARM) that is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a

115 PET ligand (68)Ga-NOTA-AE105, targeting the urokinase-type plasminogen activator receptor (uPAR), an

116 surface or secreted factors, including CD73, urokinase-type plasminogen activator receptor (uPAR), an

117 se partitioning, co-immunoprecipitation with urokinase-type plasminogen activator receptor (uPAR), an

118 ulin-like growth factor-II, plasminogen, and urokinase-type plasminogen activator receptor (uPAR), to

119 g the genes identified, we discovered that a urokinase-type plasminogen activator receptor (uPAR)/int

120 ling pathways downstream of the EGFR and the urokinase-type plasminogen activator receptor (uPAR); ho

121 The urokinase-type plasminogen activator receptor (uPAR, CD8

122 dinated by many receptors, in particular the urokinase-type plasminogen activator receptor (uPAR, CD8

123 18, Mac-1) forms a physical complex with the urokinase-type plasminogen activator receptor (uPAR/CD87

124 through the interaction with a region of the urokinase-type plasminogen activator receptor (uPAR88-92

125 phosphatidylinositol-linked proteins such as urokinase-type plasminogen activator receptor and endoth

126 ein 7 ([TIMP-2] x [IGFBP7]), and the soluble urokinase-type plasminogen activator receptor are of dia

127 [TIMP-2] x [IGFBP7] and soluble urokinase-type plasminogen activator receptor are promis

128 n of epidermal growth factor receptor and/or urokinase-type plasminogen activator receptor in a varie

129 ive action of cell surface-associated HS and urokinase-type plasminogen activator receptor in the acc

130 Soluble urokinase-type plasminogen activator receptor levels at

131 [IGFBP7] levels over time and serum soluble urokinase-type plasminogen activator receptor levels onc

132 Soluble urokinase-type plasminogen activator receptor performed

133 ncoding the antimicrobial peptides antigen-6/urokinase-type plasminogen activator receptor related pr

134 r, urokinase-type plasminogen activator, and urokinase-type plasminogen activator receptor, along wit

135 that high basal VEGF, glucose transporter-1, urokinase-type plasminogen activator receptor, and plasm

136 , including plasminogen, thrombomodulin, the urokinase-type plasminogen activator receptor, and to a

137 ated targets of note from this study include urokinase-type plasminogen activator receptor, serine/th

138 the rise of nephropathy biomarkers, soluble urokinase-type plasminogen activator receptor, suPAR and

139 in studies of SLURP (secreted mammalian Ly-6/urokinase-type plasminogen activator receptor-related pr

140 The overexpression of urokinase-type plasminogen activator receptors (uPARs) r

141 Urokinase-type plasminogen activator receptors (uPARs),

142 Single-chain urokinase-type plasminogen activator (scu-PA) possesses

143 asis of the interaction between single-chain urokinase-type plasminogen activator (scuPA) and its rec

144 A recombinant prodrug, single-chain urokinase-type plasminogen activator (scuPA) fused to an

145 precursor of PSA (pro-PSA) and single chain urokinase-type plasminogen activator (scuPA, pro-uPA).

146 e acetate-induced MMP-9 secretion but not of urokinase-type plasminogen activator secretion.

147 in vivo efficacy of mAb16-71 in "human liver urokinase-type plasminogen activator, severe combined im

148 , cathepsin G, and plasma kallikrein but not urokinase-type plasminogen activator, tissue plasminogen

149 rine proteases thrombin, plasmin, factor Xa, urokinase-type plasminogen activator, tissue plasminogen

150 ty of C4BP, the activation of plasminogen by urokinase-type plasminogen activator to active plasmin w

151 complexes of PAI-1 with low-molecular-weight urokinase-type plasminogen activator to LRP1.

152 Mice carrying an albumin-urokinase type plasminogen activator transgene (AL-uPA)

153 ytes into the liver of mice that contain the urokinase-type plasminogen activator transgene (uPA) and

154 To test our hypothesis, we directed murine urokinase-type plasminogen activator transgene expressio

155 Human urokinase type plasminogen activator (u-PA) is a member

156 uantitative image analysis for assessment of urokinase-type plasminogen activator (u-PA) and PAI-1.

157 re, 1 min after PHx, but not sham operation, urokinase-type plasminogen activator (u-PA) and u-PA rec

158 ase trypsin and the highly specific protease urokinase-type plasminogen activator (u-PA).

159 tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA).

160 ostasis after injury following activation by urokinase-type plasminogen activator (u-PA; encoded by t

161 r extent) were found to drastically increase urokinase type plasminogen activator (uPA) and matrix me

162 s of normal scars and keloids expressed both urokinase type plasminogen activator (uPA) and plasminog

163 ase (MAPK), cytosolic phospholipase A(2) and urokinase type plasminogen activator (uPA) are required

164 h the type of protease (trypsin, thrombin or urokinase type plasminogen activator (uPA)).

165 Urokinase-type plasminogen activator (uPA) activates the

166 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) activities in

167 Matrix metalloproteinase (MMP), plasmin, and urokinase-type plasminogen activator (uPA) activities we

168 ographic procedure that specifically detects urokinase-type plasminogen activator (uPA) activity in b

169 In untreated animals both tPA and urokinase-type plasminogen activator (uPA) activity was

170 Although maspin does not directly inhibit urokinase-type plasminogen activator (uPA) activity, we

171 (MMP) detection and a colorimetric assay for urokinase-type plasminogen activator (uPA) analysis, we

172 Here, we show that neurons release urokinase-type plasminogen activator (uPA) and astrocyte

173 specifically inhibit cell surface-associated urokinase-type plasminogen activator (uPA) and fibrinoge

174 nizes the N-terminal growth factor domain of urokinase-type plasminogen activator (uPA) and is expres

175 The high affinity interaction between the urokinase-type plasminogen activator (uPA) and its glyco

176 Pancreatic carcinomas express high levels of urokinase-type plasminogen activator (uPA) and its recep

177 Urokinase-type plasminogen activator (uPA) and its recep

178 Urokinase-type plasminogen activator (uPA) and its recep

179 Interaction between the urokinase-type plasminogen activator (uPA) and its recep

180 The role of urokinase-type plasminogen activator (uPA) and its recep

181 assess whether preoperative plasma levels of urokinase-type plasminogen activator (uPA) and its solub

182 1) and diminishing the enzymatic activity of urokinase-type plasminogen activator (uPA) and matrix me

183 Urokinase-type plasminogen activator (uPA) and plasmin,

184 as reduced and extracellular accumulation of urokinase-type plasminogen activator (uPA) and plasminog

185 d the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminog

186 models focus on the ability of uPAR to bind urokinase-type plasminogen activator (uPA) and promote p

187 tein, p53, and apoptosis with suppression of urokinase-type plasminogen activator (uPA) and the uPA r

188 sly demonstrated that the expression of both urokinase-type plasminogen activator (uPA) and the uPA r

189 Leukocytes express both urokinase-type plasminogen activator (uPA) and the uroki

190 activity capable of cleaving a substrate for urokinase-type plasminogen activator (uPA) and tissue pl

191 rpin inhibitor of the plasminogen activators urokinase-type plasminogen activator (uPA) and tissue pl

192 in, we investigated the upstream activators, urokinase-type plasminogen activator (uPA) and tissue-ty

193 ay regulate cardiac fibrosis by inactivating urokinase-type plasminogen activator (uPA) and ultimatel

194 In addition, urokinase-type plasminogen activator (uPA) and uPA recep

195 The urokinase-type plasminogen activator (uPA) and uPA recep

196 F-induced invasion, UM-SCC-1 cells expressed urokinase-type plasminogen activator (uPA) and uPA recep

197 tor (VLDLr) binds diverse ligands, including urokinase-type plasminogen activator (uPA) and uPA-plasm

198 Urokinase-type plasminogen activator (uPA) and vitronect

199 al oncospheres upregulated the expression of urokinase-type plasminogen activator (uPA) and/or matrix

200 Mice lacking urokinase-type plasminogen activator (uPA) are highly su

201 s cells produced more of the serine protease urokinase-type plasminogen activator (uPA) as compared w

202 his study identifies the extracellular PAI-1/urokinase-type plasminogen activator (uPA) balance as an

203 Urokinase-type plasminogen activator (uPA) binds to cell

204 Urokinase-type plasminogen activator (uPA) bound to a si

205 crystal structures of trypsin, thrombin, and urokinase-type plasminogen activator (uPA) bound with a

206 Induction of the urokinase-type plasminogen activator (uPA) by hepatocyte

207 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) decreased und

208 t of peripheral tolerance) actually produced urokinase-type plasminogen activator (uPA) during tolera

209 Sustained urokinase-type plasminogen activator (uPA) expression is

210 Both FGF-2 and phorbol ester-inducible urokinase-type plasminogen activator (uPA) expression re

211 ase C (PKC) activity leading to up-regulated urokinase-type plasminogen activator (uPA) expression.

212 pe plasminogen activator (tPA) gene, and the urokinase-type plasminogen activator (uPA) gene.

213 Of particular importance, urokinase-type plasminogen activator (uPA) has been show

214 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) in liver repa

215 Urokinase-type plasminogen activator (uPA) induces cell

216 The urokinase-type plasminogen activator (uPA) is a serine p

217 Urokinase-type plasminogen activator (uPA) is a serine p

218 Urokinase-type plasminogen activator (uPA) is a serine p

219 Urokinase-type plasminogen activator (uPA) is a serine p

220 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) is associated

221 Urokinase-type plasminogen activator (uPA) is expressed

222 Urokinase-type plasminogen activator (uPA) is expressed

223 We have previously demonstrated that urokinase-type plasminogen activator (uPA) is highly exp

224 Urokinase-type plasminogen activator (uPA) is increased

225 hypothesized that Mp-specific expression of urokinase-type plasminogen activator (uPA) is sufficient

226 We recently proposed that a proteinase, urokinase-type plasminogen activator (uPA) may be added

227 Urokinase-type plasminogen activator (uPA) participates

228 Plasminogen activation catalyzed by urokinase-type plasminogen activator (uPA) plays an impo

229 The urokinase-type plasminogen activator (uPA) promoter cont

230 We hypothesized that urokinase-type plasminogen activator (uPA) promotes musc

231 The urokinase-type plasminogen activator (uPA) receptor (uPA

232 The interaction of the urokinase-type plasminogen activator (uPA) receptor (uPA

233 ree-domain clamp of Argos also resembles the urokinase-type plasminogen activator (uPA) receptor, whi

234 Genetic absence of the urokinase-type plasminogen activator (uPA) reduces arthr

235 Urokinase-type plasminogen activator (uPA) regulates ang

236 Urokinase-type plasminogen activator (uPA) regulates the

237 ave a significant reduction in expression of urokinase-type plasminogen activator (uPA) relative to t

238 Urokinase-type plasminogen activator (uPA) stimulates MC

239 The urokinase-type plasminogen activator (uPA) system has be

240 Recent studies indicate that binding of the urokinase-type plasminogen activator (uPA) to its high-a

241 The binding of urokinase-type plasminogen activator (uPA) to its recept

242 Binding of the urokinase-type plasminogen activator (uPA) to its recept

243 Binding of urokinase-type plasminogen activator (uPA) to its recept

244 Binding of urokinase-type plasminogen activator (uPA) to its recept

245 Plasminogen activation by urokinase-type plasminogen activator (uPA) was markedly

246 ssays and plasminogen zymography showed that urokinase-type plasminogen activator (uPA) was responsib

247 n with bovine trypsin, rat trypsin and human urokinase-type plasminogen activator (uPA) were investig

248 Interaction of urokinase-type plasminogen activator (uPA) with its rece

249 Urokinase-type plasminogen activator (uPA)(-/-) mice can

250 ession was inversely correlated with that of urokinase-type plasminogen activator (uPA), a prometasta

251 We hypothesized that urokinase-type plasminogen activator (uPA), a protease i

252 a receptor for the plasmin-producing enzyme urokinase-type plasminogen activator (uPA), and can also

253 increased inflammation, increased levels of urokinase-type plasminogen activator (uPA), and greater

254 such as matrix metalloproteinase (MMP)-9 and urokinase-type plasminogen activator (uPA), in human pro

255 ficient cells, which secreted high levels of urokinase-type plasminogen activator (uPA), invaded exte

256 The trypsin-like serine protease, urokinase-type plasminogen activator (uPA), is central i

257 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), is mediated

258 The plasminogen/plasmin system, urokinase-type plasminogen activator (uPA), its receptor

259 of tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), its receptor

260 we found that the expression of epiregulin, urokinase-type plasminogen activator (uPA), matrix metal

261 We report that the urokinase-type plasminogen activator (uPA), one of the c

262 g factors, such as interleukin (IL)-8, IL-6, urokinase-type plasminogen activator (uPA), or uPA recep

263 Tobacco smoke induced the expression of urokinase-type plasminogen activator (uPA), resulting in

264 (such as Factor Xa (FXa), Factor XIa (FXIa), urokinase-type plasminogen activator (uPA), thrombin, an

265 Plasminogen can be activated to plasmin by urokinase-type plasminogen activator (uPA), tissue-type

266 processes by virtue of its interactions with urokinase-type plasminogen activator (uPA), vitronectin

267 site-directed mutant of the serine protease urokinase-type plasminogen activator (uPA), was produced

268 as applied to the screening of inhibitors of urokinase-type plasminogen activator (uPA), which is a p

269 ilencing expression of endogenously produced urokinase-type plasminogen activator (uPA), which is nec

270 In contrast to mammalian urokinase-type plasminogen activator (uPA), which is pro

271 face receptor capable of not only focalizing urokinase-type plasminogen activator (uPA)-mediated fibr

272 closed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA).

273 the largest difference being the activity of urokinase-type plasminogen activator (uPA).

274 and is required for inducible expression of urokinase-type plasminogen activator (uPA).

275 growth factor (VEGF), isomers of VEGF-A, and urokinase-type plasminogen activator (uPA).

276 Activated lymphocytes express urokinase-type plasminogen activator (uPA).

277 inhibitor 1 (PAI-1) is a major inhibitor of urokinase-type plasminogen activator (uPA).

278 emarkably selective and potent inhibitors of urokinase-type plasminogen activator (uPA).

279 luding tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA).

280 oding tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).

281 osis in transgenic livers overexpressing the urokinase-type plasminogen activator (uPA).

282 tate ecotin inhibitors for trypsin and human urokinase-type plasminogen activator (uPA).

283 LAM lesions and angiomyolipomas overexpress urokinase-type plasminogen activator (uPA).

284 peptide based on consensus cleavage motif of urokinase-type plasminogen activator (uPA).

285 iring the proteolytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metall

286 In addition, we demonstrate that the urokinase-type plasminogen activator (uPA)/uPA receptor

287 urthermore, when tyrosine phosphorylation or urokinase-type plasminogen activator (uPA)/uPAR function

288 ession in mice with targeted deficiencies in urokinase-type plasminogen activator (UPA-/-) and its in

289 Mice deficient in urokinase-type plasminogen activator (uPA-/-) exhibit de

290 The receptor for urokinase-type plasminogen activator (uPAR) plays import

291 sine phosphorylation of beta-catenin, induce urokinase-type plasminogen activator, uPAR, and cyclin D

292 studies have indicated that the receptor for urokinase-type plasminogen activator, uPAR, can form fun

293 t the active sites of trypsin, thrombin, and urokinase type plasminogen activator (urokinase or uPA)

294 Bound to BBA70, plasminogen activated by urokinase-type plasminogen activator was able to degrade

295 Single-chain urokinase-type plasminogen activator was activated using

296 ould lead to drug-entrapped vascular grafts: urokinase-type plasminogen activator was entrapped withi

297 uPA (urokinase-type plasminogen activator) was related to sys

298 by a compensatory increase in expression of urokinase-type plasminogen activator, which activates uP

299 The PLAU gene within this region encodes urokinase-type plasminogen activator, which converts pla

300 rix metalloproteinase-9 and the secretion of urokinase-type plasminogen activator while increasing ti